To determine the effect of the angiotensin II AT, receptor antagonist losartan (DuP7531 on echocardiographic left ventricular (LV! anatomy in Dahl rats on high sodium diet, 27 Dahl saltsensitive (Dahl-S, 13 on drug and 14 receiving tap water) and 27 Dahl salt-resistant rats (Dahl-R, 13 on drug and 14 receiving tap water) were studied by M-mode echocardiography during 8 weeks of 8% NaCl diet. At the endpoint !sfter 8 weeks or the last echocardiogram for animals who died earlier), D&-S receiving losartan had lower LV mass (1.6 -C 0.4 g/kg".59) than Dahl-S receiving tap water (2.2 t 0.7 g/kg0.59; P < .005), although blood pressure was only partially reduced (167 f 29 z, 195 2 52; P -,051. This difference was mainly due to lower LV wall thickness (P i .02i, with a less consistent decrease in LV chamber size in Dahl-S receiving losartan. Blood pressure was normal in Dahl-R (tap water group = 116 t 11 mm Hg; losartan group = 115 2 13 mm Ng) and losartan had no effect on LV mass (1.6 I 0.4 g/ kg".59 in both groups). In the majority of rats, echocardiographic measurements were compared between the end of second or third week and the last available study: LV mass increased in saltloaded Dahl-S receiving tap water (1.6 t: 0.6 to 2.1 + 0.7 g/kgO.", P < .tM! and was stable in Dahl-S receiving losartan (1.5 + 0.1 to 1.5 + 0.3 g/kg".59), paralleling changes in LV chamber dimension. Thus, a high salt diet leads to hypertension and eccentric LV hypertrophy in Dahl-S but not in Dahl-R. Inhibition of angiotensin II ATI receptors reduces the development of LV hypertrophy in Dahl-S rats despite lack of efficient control of blood pressure. Am J Hypertens 1996;9:216-222
LV chamber enlarge,ment and a degree of LV hype&o-phy comparable with that caused by mild renovascular hypertension.'" The mechanism by which salt intake stimulates myocardial hypertroplty is ;~obabi~ volcme-dependent: 3s suggested by previo-us stuct~es in humans" ' and animals." Among the many biological :ubstances thai may contribute to the deveiopment of LV hypertrophy, angiotensin II might play a key role because of its ability to increase both pressure overload I through systemic vasoconstriction 1 and volume owr!r:ad (throu#i aidosterone-mediated and direct renal sodium an> WIter retention). This role is also suggested by the observation of an especially consistent effect of angiotensin converting enzyme inhibitors in reducing LV hypertrophy." Whether the entire role of angiotensin II in the development of LV hypertrophy is hemodynamicaiiy mediated, or if it is in part direct, remains to be cla&ed. Little information is available on the effect of angiotensin II in influencing development of LV hypertrophy in volume-dependent forms of hypertension in which partial or even total suppression of the renin-angiotensin system may occur." Accordingly, to study the effect of angiotensin 11 activity blockade on development ol LV hypertrophy in a fezim of sodium-stimulated arierial hypertension, LV anatomy was studied during hi&: salt intake in Dahl salf-sensitive rats (Dahl-51, a model of volume-dependent hypertension, "*" and in control salt-resistant animais (Dahl-R) with or without treatment with the angintensin 11 AT1 receptor inhibitor tosartan.
METHODS

Animal Models
Twenty-seven n?a!e Da!?!-5 and 27 male Dahl-K rats (Harlan Sprague-Da&e!, lndianapoIis, IN) were studied between 19?0 and 1991 under a protocol approved by the Instituticnai Animal Care and Use Committee of Cornell University Medical College. All r&s were 6 to 7 wcwks old at the beginning of the study and were housed individuafly for c! ~vecks in metabolic cages unde.-controlled conditions of Ii& tcmperaturc, and humidity. All the animals were fed 8%, NaCI chow (Zeigier Bras., Inc., Gardners. PA) and were &owed to drink tap rrater ad Jibitum. A nonpeptide angiotensin lI receptor inhibitor, losartan (Dul' 7.53; ~-rr-butyl-4-cl~!oru-5-hydro~v~~~etl~yI-l[2'-~lW-tefrazol -S-yl)biphcnyl-~-yI]methyli~~idazole; DuPont hierik Pharmaceutical Co., Wilmington, DE) was given as a potassium salt to 13 Dahl-S and 13 Dahl-R at the dose of 30 mg/kg body weight I day disso!red in part of the drinking water. The other 14 D&l-S anrl 1-I Da&R rats .*rved as controls. Systolic blood lw2wre was measurcti weekly in a,tuaIw animals by tail cuff sp!s);gmomanomctry (1%~,XXl, Narco Rio-System, Houston, TX), the same day as recording of body weight. where 12.28 is a constant derived by a nonlinear regression analysis in a learning series of rats and validated in a test series" and lo3 converts milligrams to grams. Cross-sectional area was also computed as a measure of LV weight independent of geometric assumptions.8 Diastolic relative wall thickness, calculated as (PWT + IVS)/EDD, was used as an additional index of LV geometry. ' Echocardiographic LV mass and cross-sectional area were closely related to necropsy weight (R 2 0.90, P < .OOOl ) in sequential learning and test series of rats.r7"r Normalization for bodv size was obtained using body weight to the approphate power to linearize its relations with LV mass (exponent = 0.591, cross-sectionaI area (exponent = 0.533), and LV diastolic dimension (exponent = 0.21), as previously reported in detail.' For convenience LV mass/body wei@@" will be called LV mass index.
Statistical Analysis
Data are presented as mean 2 standard deviation. Distributions of variables used in this studg were examined by the Shapiro-Wilk Test and found to deviate from normality. Thus, 1ogarithrnGc transformation was used for analysis of variance. Twoway ANOLTA >with post hoc computation of simple main effects was used to detect the eftect of treatment in either strain of rats at t>!e end of the study. Analysis of variance for repeated measurements was used to compare changes over tune between the second or third week and final echocardiograms among the groups of experimental animals. The null hypothesis was rejected at a two-tailed P I "05.
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RESULTS
Among the rats studied, 4 Dahl-S receiving tap water (29%), 9 Dahl-S receiving losartan (69%), 12 Dahi-K receiving tap water (86% 1, and 11 Dahl-R receiving losartan (85%) survived through the end of the study.
The other animals were found dead in their cages. At the time of last echocardiogram, body weight was lower (P < .OOOl ) in Dahl-S (311 !I 47 g receiving tap water and 352 t 28 g receiving losartan, P < .002) than in Dahl-R (374 2 29 g receiving tap water and 388 2 27 g receiving losartan, P = NS), pdrtially due to the fact that the endpoint echocardiogram occurred at the end of the fifth, sixth, or seventh week in 10 of 14 Dahi-S receiving tap water. Blood pressure was significantly higher in Dahl-S than in Dahl-R groups (P < .OOOl ). Blood pressure in Dahl-S receiving losartan was slightly lower than in Dahl-S receiving tap water (167 t 29 mm Hg z? 195 t 52 mm Hg; P = .05); no difference was noted in Dahl-R (116 ?I 11 mm Hg receiving tap water; 115 t 13 mm Hg receiving losartan). Table 1 shows blood tests of animals that survived until being killed at the eighth week of salt loading: in Dahl-S receiving tap water, plasma renin activity was very high (P < .0003 ZI Dahl-R receiving tap water), hematocrit was reduced (P < .Ol u the other groups), and clearance of creatinme was low (P < .005 D the other groups). Urinary protein excretion was higher in both groups of Dahl-S than in Dahl-R, independent of therapy (P < .0002). ANF tended to be higher in both Dahl-S and Dahl-R treated with losartan, but differences did not attain statistical significance, because of both the high within-group variance and the small number of animals in each cell. Table 2 shows that after 5 to 8 weeks Xo difference was observed between the two Dahl-R groups. Difference in LV mass between the two Dahl-S groups was due predominately to higher wall thickness in Dahl-S receiving tap water, a difference that reached statistical significance for the posterior wall (P < .05, Table 2 ) and for the sum of posterior wall and septum (P < .02). Because LV chamber dimension was also slightly greater in Dal&S receiviig tap water than in Dahl-S receiving losartan, relative wall thickness was not significantly elevated in the former group of rats (Table 2 ). Endocardial fractional shortening was higher in pooled Dahl-S than in pooled Dahl-R (P < .05), but no significant drug effect was detected in either strain (Table 2) . Longitudinal Change; in Left Ventricular Geometry Within-group comparison was made between the echocardiographic studies at the end of second or third week of high-salt diet and at the end-study in 10 Dahl-S receiving tap water, 11 Dahl-S receiving losartan, 12 Dahl-R receiving tap water, and 9 Dahl-R receiving losartan.
Patterns of Left Ventricular Geometry in Experimental Animals
At the time of the first available echocardiogram, blood pressure was statistically indistinguishable in all groups (Table 3 ). Blood pressure increased over time in all four groups (.OOOl < P < XX), belt this i,z,ase was more proncmced in Dahl-S than in Dab!-R on either treatment (P < .02 with tap water and P = .08 with losartan). Figure 1 shows that LV mass index increased over time in DahlS receiving tap water, but was stable in Dal&S receiving losartan. The difference in LV mass between the Dahl-S groups was insignificant at the time of first echocardiogram, but became highly significant at the end of the study (P < .OOl), due to a greater irkcrease in LV chamber dimension in D&l-S receiving tap water than in Da>&S roe&v&g losartzr, (betweezgroup P < .02, Figure 2 ). Relative wall thickness did not change significantly.
LV mass index did not change significantly over time in either group of Dahl-R rats (1.67 ? 0.24 ?I 1.63 i 0.36 g/kgo-59 receiving tap water and 1.62 P C.3; 3 1.45 1. 0.27 g / kg",99 receiving losartani .
DISCUSSION
This study was designed to assess changes in LV geometry in a model of sodium-stimulated arterial hypertension, without primary dependence on renin-angiotensin system activity, to determine whether or not development of LV hypertrophy can be influenced by blocking the action of angiotensin II, The strain of Dahl and 2.21 g/kg0.82 in two-kidney shams) on a less eytremely (4% ZI 8%) high salt diet.'" This difference cannot be due to the different methods used to calculate LV mass in the present and in the previous study," because validation studies'T2' have shown that bath approaches yield very similar values of LV mass. Thus, Dal&R show partial protection against hemodynamitally-mediated cardiac changes induced by salt loading, possibly associated with their exceptional capacity to increase their glomerular filtration rate.= Conversely, a marked increase in LV mass occurred in untreated hypertensive Dahl-S rats, confirming that the combination of both pressure and volume overload dramatically stimulates development of LV hypertrophy.5,'0 This increase in LV mass was completely inhibited in rats treated with 10s. -tan, although the drug was not as effective in reducing blood pressure as has been previously reported with diuretic therapy.23 Because relative wal! thickness remained normal in our untreated Dahl-S that developed LV hypertrophy, whereas LV chamber dimension was increased, the increased LV mass resulted in eccentric LV hypertrophy, a geometric pattern associated with volume overload.6,' At lower dietary sodium concentration (4%), no effect has been reported for losartan on LV geometry after 7 weeks of salt loading in Dahl-S, even at higher doses of losartan." In that study, the necropsy mean LV mass index in rats receiving tap water was 2.59 g/kg, corresponding to about 1.53 g/'kg'.", a value markedly lower than the average value detected in our Dahl-5 on S% sodium diet. In addition to the different levels of hemodynamic overload produced by the two different sodium concentrations, in our study the potential survivor effect ( ie, rats with less severe cardiac involvement 1 was avoided by using the last echocardiogram available for the study before spontaneous death. In our study, indeed, LV mass index was much lower in the four Dahl-S that survived to the end of the trial (1.53 t 0.25 g/kg'.") than in animals who died before the eighth week (2.38 ?z 0.75 g/kg0.59).
Mechanisms Underlying the Effect of Angiotensin II Receptor Inhibition An important consideration is whether angiotensin II receptor inhibition dLcctly affected development of LV hypertrophy, as has been previously suggested.% Long-term losartan treatment did not induce any significant difference in measures of LV mass or chamber size in Dahl-R on high salt diet compared to tap water-treated Dahl-R. The subztantially lower LV mass in losartan-treated Dahl-S comfiared to tap water-treated animals (29% reduction) is in line with that expected for a 7% lower indexed LV dimension (Table 2 ) and an 14% lower systolic blood pressure, suggesting it may have been due to parallel decreases in both LV volume and pressure loads. This interpretation is indirectly supported by evidence from previous studies on human essentialz6 and renovascularz7 hypertension, as well as experimental renovascular hypertension'" in which activation of the renin-angiotensin system did not appear to add to the level of hemodynamic load as a stimulus to LV hypertrophy. However, in the present study, losartan only partially blocked the tendency for Dahl-S to increase LV chamber size during serial echocardiograms (Figure 2 ) and losartan's effect on LV mass in Dahl-S appeared to be due mostly to a reduction in wall thickness, a decrease that exceeded that expected for the measured difference in arterial pressure.
CONCLUSIONS
High salt intake stimulates development of eccentric LV hypertrophy in Dahl-S rats. Inhibition of angiotensin II AT1 receptors blunts the development of LV hypertrophy in Dahl-S rats, despite only partial control of blood pressure, possibly due to control of concomitant volume overload or to direct nonhemodynamic effects. 
